Outcome differences between first and second-generation EGFR inhibitors in advanced EGFR mutated NSCLC in a large population-based cohort

Published 2019 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Outcome differences between first and second-generation EGFR inhibitors in advanced EGFR mutated NSCLC in a large population-based cohort
Authors
Keywords
Afatinib, Erlotinib, Gefitinib, Real-world population, TKI
Journal
Clinical Lung Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2019-05-11
DOI
10.1016/j.cllc.2019.05.003

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.